Beigene, LTD Form 4 insider transactions

BeiGene, Ltd. Director Yi Qingqing has reported the acquisition of 10,985 restricted share units and 22,750 share options, aligning her interests with shareholders and reinforcing long-term commitment.

Director Shalini Sharp reports acquiring 10,985 ordinary shares and disposing of 0 shares, while also acquiring 22,750 share options in BeiGene, Ltd.

Director Brandicourt Olivier reports acquisition and disposal of BeiGene, Ltd. shares and options.

Director Alessandro Riva acquired shares and options in BeiGene, Ltd. on May 21, 2025, according to a Form 4 filing.

Director Margaret Dugan reports acquisition of BeiGene shares and options, including restricted share units and share options, under the company's Independent Director Compensation Policy.

Director Corazon Sanders acquired shares and options in BeiGene, Ltd. on May 21, 2025, according to a Form 4 filing.

Director Anthony C. Hooper reports acquisition of ordinary shares and grant of share options in BeiGene, Ltd.

Baker Bros. Advisors and related entities report changes in beneficial ownership of BeiGene, Ltd. ordinary shares and share options due to grants of restricted stock units and share options to their employees serving as BeiGene directors.

Director Wang Xiaodong exercised share options and sold American Depositary Shares of BeiGene, Ltd. under a pre-arranged Rule 10b5-1 trading plan.

CEO John Oyler exercised stock options and had shares withheld for tax obligations, resulting in changes to his beneficial ownership of BeiGene, Ltd. shares.

Director Wang Xiaodong reports the sale of BeiGene American Depositary Shares (ADS) on April 14, 2025, under a pre-arranged Rule 10b5-1 trading plan.

BeiGene's President, COO & GM China, Wu Xiaobin, reports multiple transactions involving American Depositary Shares (ADS) and share options, including sales executed under a Rule 10b5-1 trading plan.

Director Wang Xiaodong of BeiGene, Ltd. reports the sale of American Depositary Shares (ADS) under a pre-arranged Rule 10b5-1 trading plan.

Wu Xiaobin, President, COO & GM China of BeiGene, Ltd., reports a transaction involving RMB Shares through an employee participation program.

Director Xiaodong Wang reported a gift of 158,717 ordinary shares of BeiGene, Ltd.

BeiGene's CEO, John Oyler, executed share options and sold a portion of his American Depositary Shares (ADS) on March 10, 2025, to cover exercise costs and tax obligations.

BeiGene's CEO, John Oyler, exercised share options and sold American Depositary Shares (ADS) on March 7, 2025, to cover the exercise cost and tax obligations.

BeiGene's CEO, John Oyler, reports the acquisition and disposal of ordinary shares and American Depositary Shares (ADS) related to option exercises and tax obligations.

Wu Xiaobin, President, COO & GM China of BeiGene, Ltd., reports the acquisition and disposal of company shares and the exercise of stock options on March 5, 2025.

Lai Wang, Global Head of R&D at BeiGene, reports acquisition and disposal of ordinary shares and indirect interest in RMB shares through an employee participation plan.

Chan Henry Lee, SVP and General Counsel of BeiGene, Ltd., reports acquiring and disposing of ordinary shares on March 5, 2025, according to a Form 4 filing.

Aaron Rosenberg, CFO of BeiGene, Ltd., reports acquiring and disposing of ordinary shares, including performance share units, in a recent transaction.

Director Wang Xiaodong sold American Depositary Shares of BeiGene, Ltd. on March 4, 2025, under a pre-arranged Rule 10b5-1 trading plan.

BeiGene CEO John Oyler exercised share options and sold American Depositary Shares (ADS) on March 3, 2025, according to a Form 4 filing with the SEC.

Xiaobin Wu, President, COO & GM China of BeiGene, Ltd., reports a disposition of economic interest in RMB Shares through an employee participation plan.

Chan Henry Lee, SVP and General Counsel of BeiGene, Ltd., sold 1,205 American Depositary Shares on February 27, 2025, at a price of $275 per share, according to a Form 4 filing with the SEC.

Baker Bros. Advisors LP reports the sale of 671,976 American Depositary Shares (ADS) of BeiGene, Ltd. at $260 per share on February 28, 2025, alongside other transactions affecting their holdings.

Lai Wang, Global Head of R&D at BeiGene, Ltd., reports the sale of American Depositary Shares (ADS) on February 21, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Chan Henry Lee, SVP and General Counsel of BeiGene, Ltd., sold American Depositary Shares (ADS) under a pre-arranged Rule 10b5-1 trading plan.

Xiaobin Wu, President, COO & GM China of BeiGene, Ltd., exercised stock options and sold American Depositary Shares (ADS) between February 18 and February 20, 2025, according to a recent SEC filing.